查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1622105

全球骨盆器官脫垂設備市場規模（按設備、應用、最終用戶、地區、範圍和預測）

Global Pelvic Organ Prolapse Devices Market Size By Device (Vaginal Pessary, Vaginal Mesh), By Application (Surgical Devices, Non-Surgical Devices), By End-User (Hospitals, Ambulatory Surgical Centers), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

骨盆腔器官脫垂設備的市場規模及預測

2022 年骨盆腔器官脫垂設備市場規模價值為 1.8536 億美元，預計到 2030 年將達到 4.0512 億美元，2023 年至 2030 年的複合年增長率為 4.12%。預計全球老年人口的增加和老齡女性人口中 POP 盛行率的上升將在未來幾年推動骨盆器官脫垂設備市場的發展。全球骨盆器官脫垂設備市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

骨盆腔器官脫垂設備的全球市場定義

骨盆腔器官脫垂是由於骨盆區域支撐組織和肌肉變弱或鬆弛而發生的疾病。雖然這種疾病是可以治療的，但骨盆器官脫垂裝置旨在支撐骨盆器官，包括膀胱、子宮、小腸和部分陰道。

膀胱脫垂稱為膀胱膨出。另一方面，小腸脫垂稱為腸瘺。直腸脫垂稱為直腸膨出。治療骨盆腔器官脫垂的裝置包括陰道托和陰道網片。這些儀器可用於手術和非手術器械等應用。骨盆腔器官脫垂設備的最終使用者包括醫院、門診手術中心等。

骨盆器官脫垂設備的全球市場概況

預計全球老年人口的增加和老齡女性人口中 POP 盛行率的上升將在未來幾年推動骨盆器官脫垂設備市場的發展。除此之外，醫療保健支出在過去幾十年中呈指數級增長，預計在預測期內也將呈現類似的趨勢。這可能會在未來幾年進一步促進骨盆腔器官脫垂設備的採用。根據世界衛生組織（WHO）發佈的數據，骨盆腔器官脫垂是60-69歲女性最常見的疾病之一。約 37% 的 POP 患者年齡在 60 至 70 歲之間，超過一半的患者年齡超過 80 歲。

除此之外，骨盆器官脫垂修復治療的技術進步和持續的研究開發以及對女性健康的認識的提高預計將在未來幾年推動市場的發展。然而，某些限制和課題阻礙了市場的成長。缺乏科學的療效和安全性、手術費用高、監管規範和標準複雜等因素在一定程度上限制了需求。

目錄

第 1 章全球骨盆腔器官脫垂設備市場：簡介
    市場概況
  • 研究範圍
  • 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

  • 資料探勘
  • 驗證
  • 第一次面試
  • 資料來源列表

第 4 章骨盆腔器官脫垂設備的全球市場前景
  • 概述
  • 市場動態
    • 驅動程式
    • 阻礙因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球骨盆腔器官脫垂設備市場（按設備）

  • 概述
  • 陰道栓劑
  • 陰道網片
第6章 全球骨盆腔器官脫垂設備市場（依應用）
  • 概述
  • 手術器械
  • 非手術設備

第7章 全球骨盆腔器官脫垂設備市場（依最終用戶劃分）

  • 概述
  • 醫院
  • 門診手術中心
  • 其他

第8章全球骨盆腔器官脫垂設備市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
    亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第 9 章全球骨盆腔器官脫垂設備市場：競爭格局
  • 概述
  • 各公司的市場排名
  • 主要發展策略

第10章 公司簡介

  • Johnson & Johnson Services, Inc.
  • Coloplast Pty Ltd
  • Boston Scientific Corporation
  • CooperSurgical, Inc.
  • Dr. Arabin GmbH & Co. KG
  • Integra LifeSciences
  • Utah Medical Products, Inc.
  • Tic Med
  • Cleo
  • Shenzhen XFT Medical Limited
  • Sunmedix Co, Ltd.
  • Verity Medical Ltd
  • Neomedic
  • Medtronic
第 11 章：公司簡介 - 主要發展
  • 產品發佈/開發
  • 合併和收購
  • 業務擴展
  • 夥伴關係和合作關係

第 12 章附錄

  • 相關研究
簡介目錄
Product Code: 15371

Pelvic Organ Prolapse Devices Market Size And Forecast

Pelvic Organ Prolapse Devices Market size was valued at USD 185.36 Million in 2022 and is projected to reach USD 405.12 Million By 2030 , growing at a CAGR of 4.12% from 2023 to 2030. The increasing global geriatric population and rising prevalence of POP in the aging female population are expected to drive the Pelvic Organ Prolapse Devices Market over the predicted years. The Global Pelvic Organ Prolapse Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pelvic Organ Prolapse Devices Market Definition

Pelvic organ prolapse is a condition that occurs after the supporting tissues and muscles become weak or loose in the pelvic region. Though the disease is treatable, pelvic organ prolapse devices are meant to provide support to the pelvic organs including the bladder, uterus, small intestine, and part of the vagina.

The prolapse of the bladder is known as a cystocele. While prolapse of the small bowel is known as enterocele. If there's a prolapse of the rectum, it is known as a rectocele. The devices for pelvic organ prolapse are vaginal pessary and vaginal mesh. They are used in applications including Surgical Devices and Non-Surgical Devices. End-users of pelvic organ prolapse devices are Hospitals, Ambulatory Surgical Centers, and Others.

Global Pelvic Organ Prolapse Devices Market Overview

The increasing global geriatric population and rising prevalence of POP in the aging female population are expected to drive the Pelvic Organ Prolapse Devices Market over the predicted years. Besides this, the healthcare expenditure growth has witnessed exponential growth over the past couple of decades and it is expected to show the similar trend over the forecasted period. This will further complement the adoption of pelvic organ prolapse devices over the upcoming years. As per the data published by the World Health Organization, Pelvic organ prolapse is one of the most common in disease found across the women aged 60 to 69. Around 37% of the POP patients are between 60-70 years of age and more than half of the patients are more than 80 years of age.

In addition to this, technical advancements and ngoing research and developments in pelvic organ prolapse repair treatments and the growing awareness about women's health expect a boost to the market in the coming years.The ongoing investments and frequent need for the respective treatments will create substantial opportunities over the forecasted period. However, there are certain restraints and challenges faced which can hinder market growth. Factors such as lack of scientific efficacy & safety, higher costs involved in surgeries, and complex regulatory norms and standards will restrict the demand to some extent.

Global Pelvic Organ Prolapse Devices Market: Segmentation Analysis

The Global Pelvic Organ Prolapse Devices Market is Segmented on the basis of Device, Application, End-User, and Geography.

Pelvic Organ Prolapse Devices Market, By Device

  • Vaginal Pessary
  • Vaginal Mesh

Based on Device, the market is bifurcated into Vaginal Pessary and Vaginal Mesh. The Vaginal Pessary segment is expected to hold the largest market share. The factors can be attributed to a higher preference for vaginal pessary as vaginal mesh causes bleeding which are one of the most commonly found instances wherein the pelvic organ prolapse devices are generally used.

Pelvic Organ Prolapse Devices Market, By Application

  • Surgical Devices
  • Non-Surgical Devices

Based on Application, the market is bifurcated into Surgical Devices and Non-Surgical Devices. Surgical Devices are predicted to hold the most significant CAGR in the forecasted period as surgical devices are more effective than non-surgical devices in the treatment of pelvic organ prolapse. On the other hand, non surgical devices will also significant share considering the varying needs in line with the symptoms and medication instances.

Pelvic Organ Prolapse Devices Market, By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Based on End-User, the market is bifurcated into Hospitals, Ambulatory Surgical Centers, and Others. Hospitals are anticipated to hold the largest market share. These factors can be credited to the higher rate of surgeries, growing treatment instances in the hospitals and lack of device applications in other clinics and ambulatory surgical centers. However, the ambulatory surgical centers will grow at the significant rate considering the rising awareness and ease of access.

Pelvic Organ Prolapse Devices Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • On the basis of regional analysis, the GlobalPelvic Organ Prolapse Devices Market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America led the Global Pelvic Organ Prolapse Devices Market in terms of growth, accounting for a sizable market share. The region is technologically advanced, and it was an early adoption of advanced healthcare technologies. Besides this, the strengthened healthcare infrastructure will further complement the market growth.

Key Players

  • The "Global Pelvic Organ Prolapse Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Johnson & Johnson Services, Inc., Coloplast Pty Ltd, Boston Scientific Corporation, CooperSurgical, Inc., Dr. Arabin GmbH & Co. KG, Integra LifeSciences, , Utah Medical Products, Inc., Tic Med, Cleo, Shenzhen XFT Medical Limited, Sunmedix Co, Ltd., Verity Medical Ltd, Neomedic, and Medtronic among others.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In March 2020, the pelvic organ prolapse devices manufacturers, Fotofinder Zsystems Inc. has rebranded automated total body mapping systems as total body dermoscopy, allowing for immediate evaluation of dermoscopic structures of oles on full body photos.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
  • Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Pelvic Organ Prolapse Devices market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in global Pelvic Organ Prolapse Devices market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY DEVICE

  • 5.1 Overview
  • 5.2 Vaginal Pessary
  • 5.3 Vaginal Mesh

6 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Surgical Devices
  • 6.3 Non-Surgical Devices

7 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Ambulatory Surgical Centers
  • 7.4 Others

8 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Johnson & Johnson Services, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Coloplast Pty Ltd
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Boston Scientific Corporation
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CooperSurgical, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Dr. Arabin GmbH & Co. KG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Integra LifeSciences
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Utah Medical Products, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Tic Med
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Cleo
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Shenzhen XFT Medical Limited
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Sunmedix Co, Ltd.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Verity Medical Ltd
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Neomedic
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Medtronic
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research